Rationale and design of the multicenter, national, randomized, open labeled phase III trial: allogeneic stem cell transplantation as a potential curative treatment for patients with relapsed or progressed multiple myeloma (AlloRelapseMM Study)
Even though major improvements have been made in the treatment of myeloma, the majority of patients eventually relapse or progress. Patients with multiple myeloma who relapse after initial high-dose chemotherapy with autologous stem cells have a median progression free survival up to 2-3 years, depe...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
[27 January 2025]
|
| In: |
BMC cancer
Year: 2025, Volume: 25, Pages: 147-1-147-16 |
| ISSN: | 1471-2407 |
| DOI: | 10.1186/s12885-025-13503-7 |
| Online Access: | Verlag, kostenfrei, Volltext: https://doi.org/10.1186/s12885-025-13503-7
|
| Author Notes: | Annemarie Glöckner, Stefan Schönland, Hermann Einsele, Nicolaus Kröger |
| Summary: | Even though major improvements have been made in the treatment of myeloma, the majority of patients eventually relapse or progress. Patients with multiple myeloma who relapse after initial high-dose chemotherapy with autologous stem cells have a median progression free survival up to 2-3 years, depending on risk factors such as previous remission duration. In recent years, growing evidence has suggested that allogeneic stem cell transplantation could be a promising treatment option for patients with relapsed or progressed multiple myeloma. However, prospective randomized trials including allogeneic stem cell transplantation as second-line therapy do not exist to date and therefore urgently needed to demonstrate the value of this therapy in the overall setting of patients with multiple myeloma. |
|---|---|
| Item Description: | Gesehen am 06.08.2025 |
| Physical Description: | Online Resource |
| ISSN: | 1471-2407 |
| DOI: | 10.1186/s12885-025-13503-7 |